Tempest Therapeutics, Inc. (TPST) — 8-K Filings

8-K Filings (15)

• 8-K Filing — May 6, 2026
• Tempest Therapeutics Files 8-K with Financial Updates — Mar 30, 2026 Risk: medium
  On March 30, 2026, Tempest Therapeutics, Inc. filed an 8-K report detailing its financial results and condition. The filing includes information related to its
• Tempest Therapeutics Files 8-K on Equity Sales — Nov 26, 2025 Risk: medium
  On November 24, 2025, Tempest Therapeutics, Inc. filed an 8-K report detailing unregistered sales of equity securities. The filing also includes other events an
• Tempest Therapeutics Files 8-K with Material Agreement — Jun 12, 2025 Risk: medium
  On June 11, 2025, Tempest Therapeutics, Inc. entered into a material definitive agreement. The company also made a Regulation FD disclosure and reported other e
• Tempest Therapeutics Relocates Principal Executive Offices — Jun 11, 2025 Risk: low
  On June 11, 2025, Tempest Therapeutics, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 2000 Sierra Poin
• Tempest Therapeutics Files 8-K on Leadership and Compensation Changes — Jun 6, 2025 Risk: medium
  On June 5, 2025, Tempest Therapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing
• Tempest Therapeutics Files 8-K — Apr 28, 2025 Risk: low
  On April 24, 2025, Tempest Therapeutics, Inc. filed an 8-K report. The filing indicates that the company's principal executive offices are located at 2000 Sierr
• Tempest Therapeutics Reports Exit Costs — Apr 18, 2025 Risk: medium
  On April 17, 2025, Tempest Therapeutics, Inc. filed an 8-K report detailing costs associated with exit or disposal activities. The company, formerly known as Mi
• Tempest Therapeutics Terminates Material Agreement — Apr 9, 2025 Risk: medium
  On April 8, 2025, Tempest Therapeutics, Inc. filed an 8-K to report the termination of a material definitive agreement. The filing also includes information reg
• Tempest Therapeutics Files 8-K on Security Holder Rights — Apr 7, 2025 Risk: medium
  On April 4, 2025, Tempest Therapeutics, Inc. filed an 8-K to report material modifications to the rights of security holders and financial statements. The filin
• Tempest Therapeutics Faces Nasdaq Delisting Warning — Dec 31, 2024 Risk: high
  On December 27, 2024, Tempest Therapeutics, Inc. filed an 8-K to report its receipt of a deficiency letter from The Nasdaq Stock Market LLC. The company failed
• Tempest Therapeutics Files 8-K on Definitive Agreement — Dec 6, 2024 Risk: medium
  On December 3, 2024, Tempest Therapeutics, Inc. entered into a material definitive agreement related to its security holders. The company, formerly known as Mil
• Tempest Therapeutics Files 8-K — Oct 10, 2024 Risk: medium
  On October 7, 2024, Tempest Therapeutics, Inc. entered into a Material Definitive Agreement, the specifics of which are detailed in the filing. The company also
• Horizon to Acquire Tempest Therapeutics for $1/share + CVR — Jun 20, 2024 Risk: medium
  On June 20, 2024, Tempest Therapeutics, Inc. entered into a Material Definitive Agreement, specifically a Merger Agreement with Horizon Therapeutics plc. This a
• Tempest Therapeutics Schedules Shareholder Vote for F-star Merger — Jun 14, 2024 Risk: medium
  On June 13, 2024, Tempest Therapeutics, Inc. filed an 8-K report detailing a special meeting of stockholders scheduled for July 15, 2024. The primary purpose of

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX